[{"id":"8b8c0a41-f45d-43a3-9db7-734e8a1db874","acronym":"","url":"https://clinicaltrials.gov/study/NCT01497392","created_at":"2021-01-18T06:16:38.607Z","updated_at":"2025-02-25T15:52:26.266Z","phase":"Phase 1","brief_title":"Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers","source_id_and_acronym":"NCT01497392","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" FGFR • VEGFA","pipe":"","alterations":" ","tags":["FGFR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 03/29/2012","start_date":" 03/29/2012","primary_txt":" Primary completion: 08/31/2015","primary_completion_date":" 08/31/2015","study_txt":" Completion: 02/07/2017","study_completion_date":" 02/07/2017","last_update_posted":"2022-07-22"},{"id":"16a0661f-04b5-48f9-87e8-3e9d14716323","acronym":"","url":"https://clinicaltrials.gov/study/NCT00958971","created_at":"2021-01-17T17:55:20.778Z","updated_at":"2024-07-02T16:36:37.100Z","phase":"Phase 2","brief_title":"Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer","source_id_and_acronym":"NCT00958971","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2020-12-19"},{"id":"d4e51655-c126-480a-abc9-777a3469bb93","acronym":"","url":"https://clinicaltrials.gov/study/NCT01440959","created_at":"2021-01-18T05:58:17.058Z","updated_at":"2024-07-02T16:36:51.163Z","phase":"Phase 2","brief_title":"Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258","source_id_and_acronym":"NCT01440959","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2020-01-18"},{"id":"0e3f138d-c251-4f5f-bf20-dceb29690abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01719549","created_at":"2021-01-18T07:30:00.354Z","updated_at":"2025-02-25T15:40:29.402Z","phase":"Phase 2","brief_title":"Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1","source_id_and_acronym":"NCT01719549","lead_sponsor":"Asan Medical Center","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2020-01-07"},{"id":"c0e1b35c-39c5-4df6-93ba-f52c4664eaeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01262027","created_at":"2021-01-18T05:05:32.901Z","updated_at":"2025-02-25T15:51:33.501Z","phase":"Phase 2","brief_title":"TKI258 for Metastatic Inflammatory Breast Cancer Patients","source_id_and_acronym":"NCT01262027","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 01/27/2012","start_date":" 01/27/2012","primary_txt":" Primary completion: 11/25/2015","primary_completion_date":" 11/25/2015","study_txt":" Completion: 11/25/2015","study_completion_date":" 11/25/2015","last_update_posted":"2019-07-30"},{"id":"560d1c05-5369-4204-a6a9-9952268adb6a","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT01831726","created_at":"2021-01-18T08:08:43.044Z","updated_at":"2024-07-02T16:37:24.306Z","phase":"Phase 2","brief_title":"Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib","source_id_and_acronym":"NCT01831726 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • NTRK1 • KDR • PDGFRB • CSF1R","pipe":"","alterations":" ","tags":["FLT3 • NTRK1 • KDR • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-03-20"},{"id":"04ac85c8-bcaa-421c-a636-5b035a66e79d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01478373","created_at":"2021-01-18T06:10:09.121Z","updated_at":"2024-07-02T16:37:32.504Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib","source_id_and_acronym":"NCT01478373","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-04-27"}]